Health Economics›Breast cancer›Neoadjuvant endocrine therapy premenopausal

Neoadjuvant endocrine therapy premenopausal

Breast cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Anastrozole, Goserelin, Palbociclib Variant #01	ER	R 12 643	28d	—	—	~5	~R 53 357 indirect	—
Goserelin and Tamoxifen Variant #01	ER	R 8 293	28d	~13.0 mo	~48.0 mo	~2	~R 16 587 PFS proxy · indirect	2
Anastrozole and Goserelin Variant #01	ER	R 2 787	28d	~13.0 mo	~48.0 mo	~6	~R 16 722 PFS proxy · indirect	2

3 of 3 regimens shown